Article Text

Download PDFPDF
Where does the Occluded Artery Trial leave the late open artery hypothesis?
  1. Gervasio A Lamas1,
  2. Judith S Hochman2
  1. 1
    Mount Sinai Medical Center, Miami Beach, Florida, USA
  2. 2
    New York University School of Medicine, New York, New York, USA
  1. Dr G A Lamas, Mount Sinai Medical Center, Cardiology Research – Butler Building, 4300 Alton Road, Miami Beach FL 33140, USA; most95{at}


As of April 2007 the early open artery hypothesis is alive and well, but the late open artery hypothesis is adrift. For the foreseeable future, stable patients with persistent occlusion of the infarct artery late after myocardial infarction, and without severe ischaemia or uncontrollable angina, should be managed initially with optimal medical treatment alone, and not with percutaneous coronary intervention. Efforts should focus on establishing reperfusion earlier, including reducing the time to patient presentation.

  • open artery hypothesis
  • Occluded Artery Trial

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Competing interests: Dr Lamas has received speaking fees from CV Therapeutics, Medtronic, Guidant and Bristol-Myers Squibb, and consulting fees from CV Therapeutics and Medtronic. Dr Hochman has received consulting fees from Eli Lilly, Bristol-Myers Squibb, Sanofi Aventis, and CV Therapeutics, speaking fees from the Network for Continuing Medical Education (supported by Bristol-Myers Squibb and Sanofi Aventis) and grant support to her institution for this study from Eli Lilly, Millennium Pharmaceuticals, Schering-Plough, Guidant, and Merck.

  • Abbreviations:
    ejection fraction
    left ventricular
    myocardial infarction
    Occluded Artery Trial
    percutaneous coronary intervention